Equities

Zhongzhu Healthcare Holding Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Zhongzhu Healthcare Holding Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.65
  • Today's Change0.02 / 0.76%
  • Shares traded9.04m
  • 1 Year change+107.03%
  • Beta0.4988
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zhongzhu Healthcare Holding Co Ltd is a China-based company principally engaged in pharmaceutical manufacturing, medical services, medical devices, and real estate. The Company operates its businesses through four segments. The Real Estate Development segment is mainly engaged in real estate development and sales. The Medical segment is mainly engaged in hospital operations and medical services. The Financial Leasing segment is mainly engaged in related financial leasing business. The Pharmaceutical and Others segment is mainly engaged in medical device and pharmaceutical manufacturing. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)570.62m
  • Net income in CNY-561.59m
  • Incorporated1994
  • Employees1.25k
  • Location
    Zhongzhu Healthcare Holding Co LtdSpecial No. 1 Zhanghua South RoadZHUHAI 519020ChinaCHN
  • Phone+86 7 286402068
  • Fax+86 7 286402099
  • Websitehttp://www.zz600568.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Model Organisms Center Inc419.09m48.46m3.58bn731.0076.342.04--8.550.60180.60185.2722.510.221711.603.33573,313.102.561.152.791.2851.3048.1811.565.657.35--0.023646.614.0119.75131.56-22.5163.43--
Wuxi Commercial Mansion Grand Orient Co3.53bn-1.54m3.72bn2.43k--1.17--1.05-0.0015-0.00153.993.580.63610.6542.661,454,090.000.90264.321.337.2415.7314.711.425.610.44262.580.222983.243.08-17.20-72.97-27.84-22.49-30.12
Zhongzhu Healthcare Holding Co Ltd570.62m-561.59m5.28bn1.25k--3.08--9.26-0.2818-0.28180.28690.86120.24181.487.09457,960.80-23.93-10.17-27.66-11.9910.1911.79-98.97-65.533.07-2.400.0049---18.35-5.62-80.33---55.87--
Novogene Co Ltd2.17bn175.21m6.36bn2.20k35.572.38--2.930.42950.42955.346.410.60455.533.03986,773.005.005.807.068.9942.9541.838.278.852.35--0.024610.145.456.5910.5211.481.13--
Data as of Feb 13 2026. Currency figures normalised to Zhongzhu Healthcare Holding Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.